Articles tagged with Clinical Trials
A randomized clinical trial found that avoiding aspirin as part of an antithrombotic regimen reduces bleeding events without increasing thromboembolism risk in patients with advanced heart failure treated with left ventricular assist devices. The study suggests that aspirin avoidance may be a viable option for these patients.
Treatment with obinutuzumab has been shown to preserve kidney function and prevent flares in patients with lupus nephritis. The addition of obinutuzumab to standard treatment reduced the risk of composite outcomes, such as death or treatment failure, by 60%.
A clinical trial found that high levels of anti-Ro/SSA antibodies in pregnant women are associated with an increased risk of fetal atrioventricular block (AVB), a condition that can be fatal. Home-based fetal heart rate monitoring reliably detects conduction abnormalities, potentially reducing the need for serial echocardiograms.
Bio-TCV, a typhoid conjugate vaccine developed by IVI and Bio Farma, has been licensed in Indonesia following marketing approval from BPOM. The vaccine is expected to provide protection against typhoid fever as early as 9 months of age.
A recent study published in eClinical Medicine found that the GB510/AS03 vaccine elicited a stronger antibody immune response against the ancestral SARS-CoV-2 strain compared to ChAdOx1-S. The vaccine demonstrated robust safety and efficacy, with no significant safety concerns identified.
Patients with HER2-positive breast cancer that has spread to other parts of the body survive for longer if treated with pyrotinib. The new drug targets proteins involved in HER2-positive breast cancer and shows a 22% reduction in risk of death compared to lapatinib.
Researchers found that changing treatment can lead to significant improvement in mobility and quality of life for patients with advanced Parkinson's disease. A nationwide registry is planned to develop scientifically sound guidelines for combination therapies.
Researchers discovered that patients with FSGS who received sparsentan treatment experienced improved kidney function and reduced proteinuria, a key indicator of kidney damage. The study suggests sparsentan may be a potential new treatment option for the disorder, offering hope for patients affected by FSGS.
A novel multicomponent intervention aimed at improving patient access to kidney transplants did not significantly increase the rate of completed steps in a randomized clinical trial involving 20,375 patients. The study highlights the need for sustained efforts to address barriers to transplantation globally.
Researchers found that urine biomarkers can be more accurate than serum biomarkers for detecting specific diseases. The study highlights the potential of combining urinary and serum biomarkers for holistic disease diagnosis and management. However, challenges remain in standardizing urinary biomarker assays and expanding their applicat...
A new study from Tulane University found that frequent salt consumption is associated with a higher risk of developing Type 2 diabetes. The study surveyed over 400,000 adults and found participants who regularly added salt had a 13% to 39% increased risk of developing the disease compared to those who never or rarely used salt.
A new study by RCSI University of Medicine and Health Sciences found that boosting levels of a deficient protein improves survival rates for people with severe alpha-1 antitrypsin deficiency. The research, which tracked health data from over 600 patients, showed a clear survival benefit from augmentation therapy.
A new phase 3 clinical trial found that once-weekly basal injection of icodec to treat type 1 diabetes showed non-inferiority to daily insulin degludec in reducing HbA1C levels. However, higher rates of hypoglycaemic episodes were noted in the icodec group.
The University of Cincinnati will continue to oversee U.S. NIH-funded stroke trials for the next five years, with Pooja Khatri, MD, MSc, leading as Lead PI. The renewed infrastructure includes new features such as patient representation and advocacy initiatives, aiming to advance stroke care worldwide.
University of Alberta researchers have identified taurine as a key player in predicting poor clinical outcomes and treating long COVID. A predictive test and proposed supplement trial aim to minimize symptoms and improve patient outcomes.
A randomized clinical trial of 524 trauma patients found that adding sigh breaths to mechanical ventilation did not increase ventilator-free days. However, prespecified secondary data suggest that sighs are well-tolerated and may improve clinical outcomes in this patient population.
A randomized clinical trial involving 126 patients found that landiolol did not prevent organ failure in those with established septic shock. The study concluded that this beta-blocker is not a suitable treatment option for managing tachycardia in these patients.
A brain-computer interface (BCI) has been successfully used to restore control of home devices for a patient with ALS, allowing the individual to navigate a communication board and smart devices without recalibration. The BCI device was implanted on the surface of the brain areas responsible for speech and upper limb function, enabling...
Researchers found no significant improvement in primary composite outcomes, including organ support-free days and hospital survival, among hospitalized patients with COVID-19 who received intravenous vitamin C. The study suggests that vitamin C treatment may not be effective in improving patient outcomes for this population.
A global platform study has released results on the use of simvastatin to treat severely ill patients with COVID-19, showing a high probability of improving outcomes. In contrast, high-dose vitamin C was found to be ineffective and potentially harmful in critically ill patients, suggesting its use should be discontinued.
Tongxinluo significantly improved 30-day and 1-year clinical outcomes in STEMI patients, according to a randomized clinical trial. Further research is needed to understand its mechanism of action.
A new multitarget stool RNA test, ColoSense, has been shown to detect colorectal neoplasia with high sensitivity and comparable specificity to existing molecular diagnostic tests. The test also demonstrated significant improvement in sensitivity relative to the fecal immunochemical test.
Researchers saw a major pathologic response in over half of surgical specimens from patients treated with neoadjuvant pembrolizumab. The treatment shrank over half of advanced melanomas, according to exploratory analyses presented at the European Society of Medical Oncology (ESMO) Congress 2023.
Researchers at Penn Medicine have received a $10 million grant to develop a new strategy for preventing breast cancer recurrence by targeting dormant tumor cells. In a phase II clinical trial, the team successfully cleared dormant cells from over 80% of patients, offering a promising proof-of-concept for this approach.
A clinical trial has shown that combining chemotherapy with immunotherapy nivolumab significantly improved outcomes in patients with advanced bladder cancer. The study found nearly twice as many patients with no evidence of disease after treatment, and a median complete response of 37.1 months.
A phase III pivotal trial evaluating cabozantinib in advanced neuroendocrine tumors demonstrated significant improvements in median progression-free survival (PFS) compared to placebo. The study met its primary objective for both cohorts of patients, providing encouraging news for those with progressive disease.
A Phase III trial found that combining durvalumab and olaparib with chemotherapy reduces disease progression in advanced endometrial cancer patients by 45%, compared to 29% with durvalumab alone. The combination also shows benefits in MMR-proficient subgroups, offering new treatment options for these patients.
A secondary analysis of the SWOG S0931 trial found that patients with very-high risk clear-cell renal cell carcinoma who received adjuvant everolimus after surgery had a statistically significant improvement in recurrence-free survival. The results suggest that everolimus may be beneficial for this high-risk patient population, but als...
A randomized clinical trial found that high-frequency electrical stimulation device reduced opioid use and prescribed opioids after cesarean delivery, suggesting a potential adjunct to decrease opioid use without compromising pain control.
A new hormone replacement therapy, Pulsatility, has shown promising results in improving symptoms and quality of life for patients with adrenal insufficiency conditions. The treatment, which delivers hydrocortisone in a pulsatile pattern, decreased fatigue by 10% and improved mood and energy levels by 30%.
A retrospective study found that research staff of the same race or ethnicity as patients increased consent rates by 65.1% compared to those of a different race or ethnicity. Employing diverse research teams can improve trust and engagement among potential study participants, according to researchers.
A new cancer immunotherapy that targets two immune-evading tumor tactics has shown promising results in an early clinical trial. The drug, tebotelimab, blocks both PD-1 and LAG-3 proteins, leading to a double-digit response rate in patients with advanced solid tumors or blood cancers.
A study published in Psychological Medicine found that the widely prescribed sedative alprazolam XR may be less effective than believed, with publication bias inflating its efficacy by over 40%. This suggests caution for patients and clinicians starting a prescription for panic disorder.
In a phase I trial, an oncolytic virus treatment designed by Brigham researchers extended survival among patients with recurrent glioblastoma, especially those with pre-existing viral antibodies. The therapy reshaped the tumor's surrounding environment to stimulate an anti-tumor immune response.
A randomized clinical trial found that cefepime increased neurological dysfunction in adults hospitalized with acute infection, while piperacillin-tazobactam did not. The study involved 2,511 participants and suggested that cefepime may be associated with adverse outcomes.
A new technique to control severe bleeding in injured patients has been found to increase the risk of death. The REBOA treatment was tested in a clinical trial involving 90 adult trauma patients, but it did not show the expected benefits.
A Monash University study found that methotrexate, a low-cost and effective treatment for inflammatory joint conditions, can reduce pain and stiffness in patients with symptomatic hand OA. The study's results suggest that methotrexate may be a viable treatment option for people with hand osteoarthritis and inflammation.
Researchers conducted a randomized trial in Canadian ICUs, finding that switching to small-volume blood collection tubes lowered red blood cell transfusion rates. The study suggests this change may improve patient outcomes and reduce the need for transfusions.
The new guidelines recommend a more restrictive approach to determine optimal treatment for patients who may not need red blood cell transfusions. The panel took into account the clinical context, co-morbidities, symptoms, and signs of each patient to ensure personalized care.
A world-first clinical trial published in JAMA found that using small-volume tubes reduced the need for almost one blood transfusion for every 10 patients. The study saved about 1,500 units of blood and may provide an easy way to save tens of thousands of units worldwide.
A clinical trial led by Western Sydney University's NICM Health Research Institute has revealed that Sailuotong, a novel herbal extract, shows promise as a potential treatment for mild cognitive impairment. The study found improvements in memory and executive function in participants taking SLT compared to those on a placebo.
A new clinical trial has shown that infusing immune cells from living donors into recipients before transplantation may reduce the need for lifelong immunosuppressant medication. The treatment involves infusing donor-derived regulatory dendritic cells, which help the recipient's immune system distinguish between foreign and self-cells.
A large multi-state study found that mupirocin ointment is highly effective at preventing Staphylococcus aureus infections in critically ill patients, outperforming an antiseptic solution. The study involved over 800,000 ICU patients in 137 hospitals and showed a durable benefit from mupirocin.
Researchers discovered the STAT3 signaling pathway as a potential target for treating H3K27M-mutant diffuse midline gliomas (DMGs), a uniformly lethal central nervous system malignancy. The current standard of care, including palliative radiation and chemotherapy, remains ineffective in this disease.
A phase 2 clinical trial found that serial blood tests can identify patients who benefit from additional immunotherapies, suggesting a potential early marker of treatment response. The study also showed that ctDNA analyses correlated with tumor size and survival, making it a promising strategy for guiding therapy.
Researchers discuss lurbinectedin as a method to treat neuroendocrine tumors (NETs), with encouraging results from phase II basket studies demonstrating activity in platinum-sensitive relapsed SCLC and other malignancies. Lurbinectedin's mechanism of action involves inhibiting oncogenic transcription, promoting apoptosis and cell death.
A new study reveals that esketamine nasal spray is effective in treating treatment-resistant depression, with 27.1% of patients achieving remission after 8 weeks compared to 17.6% on quetiapine XR. Long-term data shows sustained remission rates at 21.7% for esketamine NS and 14.1% for quetiapine XR.
A post hoc analysis of 10,678 participants with atherosclerotic cardiovascular disease found no significant difference in heart attack, stroke, or death risk between enteric-coated and uncoated aspirin. Enteric-coated aspirin may offer reduced bleeding risk, but more research is needed to confirm its benefits.
A randomized clinical trial found that early metformin treatment did not improve insulin initiation or fasting glucose levels in pregnant women with gestational diabetes. Further investigation into larger trials is warranted based on prespecified secondary outcome data.
In a randomized clinical trial, weekly tirzepatide showed greater reductions in HbA1c levels and body weight compared to prandial insulin as an additional treatment in people with inadequately controlled type 2 diabetes. The study also found less hypoglycemia with tirzepatide.
Researchers at Northwestern University developed Lattice, a device that simulates human disease in multiple organs to analyze interactions and test new drugs. The technology can replicate complex disease processes, allowing scientists to study the effects of obesity on endometrial cancer, for example.
A phase 1/2 study shows that a stem cell-derived islet therapy has improved blood sugar control in all six adult patients with type 1 diabetes. Three patients achieved insulin independence and showed sustained improvements in blood glucose levels.
A new clinical trial has found that administering metformin to pregnant women with gestational diabetes does not increase adverse neonatal outcomes or maternal health risks. The study provides hope for expectant mothers and healthcare providers seeking a safe alternative to traditional insulin-based treatments.
Researchers have developed a new approach to treating invasive bladder cancer, combining chemotherapy and immunotherapy, which may preserve quality of life. In a phase 2 clinical trial, approximately 43% of patients achieved complete response without surgical removal of the bladder.
A randomized study shows that shorter radiation therapy courses are just as effective in preventing cancer return and reducing side effects for patients with breast reconstruction. The accelerated treatment regimen saved patients time, money, and experienced fewer treatment breaks.
A multi-center study found that stereotactic body radiotherapy (SABR) can achieve 100% local control and cancer-specific survival for longer than three years among patients with inoperable kidney cancer. The treatment was effective in preserving kidney function, with only one patient requiring dialysis.
Researchers found a shorter course of radiation therapy provides equivalent protection against breast cancer recurrence and physical side-effects, but reduces life disruption and financial burden. Patients reported less burden on their time and finances, with improved quality of life.
A phase III trial suggests that fewer and higher doses of radiation therapy delivered over five sessions are as effective as lower doses delivered over several weeks for patients with locally advanced disease. The treatment achieved a 96% five-year disease control rate, comparable to 95% for conventional radiation.
A new drug called vorasidenib has been shown to significantly slow tumor growth and extend the average time until tumor growth in patients with grade 2 IDH-mutant gliomas. This breakthrough could offer a first early treatment option for these cancer patients, potentially improving their quality of life.
A new study published in JAMA Network Open suggests that reattribution of pain to mind or brain processes can lead to significant reductions in chronic back pain intensity. Participants who received pain reprocessing therapy reported being pain-free or nearly so after treatment, compared to those receiving placebo controls.